Equities

Smith & Nephew PLC

SN.:LSE

Smith & Nephew PLC

Health CareMedical Equipment and Services
  • Price (GBX)1,267.00
  • Today's Change-26.50 / -2.05%
  • Shares traded2.15m
  • 1 Year change23.61%
  • Beta1.0587
Data delayed at least 20 minutes, as of Feb 06 2026 16:35 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilise severe fractures and correct bone deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.

  • Revenue in GBP (TTM)4.37bn
  • Net income in GBP360.79m
  • Incorporated1937
  • Employees17.00k
  • Location
    Smith & Nephew PLCBuilding 5, Croxley Park, Hatters LaneWATFORD WD18 8YEUnited KingdomGBR
  • Phone+44 20 7401 7646Fax+44 20 7930 3353
  • Websitehttps://www.smith-nephew.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		SN.:LSE since
announced		Transaction
value
Integrity Orthopaedics IncDeal completed12 Jan 202612 Jan 2026Deal completed0.72%450.00m
Data delayed at least 20 minutes, as of Feb 06 2026 16:35 GMT.

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
BioMerieux SA3.58bn328.03m9.74bn14.75k9.74bn14.75k
Smith & Nephew plc4.37bn360.79m10.70bn17.00k10.70bn17.00k
Sonova Holding AG3.64bn492.77m11.62bn18.04k11.62bn18.04k
Coloplast A/S3.24bn463.47m12.05bn16.98k12.05bn16.98k
Sartorius AG3.05bn116.06m13.86bn13.88k13.86bn13.88k
Sartorius Stedim Biotech SA2.56bn229.25m15.03bn10.13k15.03bn10.13k
Straumann Holding AG2.44bn405.25m15.04bn11.95k15.04bn11.95k
Data as of Feb 06 2026. Currency figures normalised to Smith & Nephew PLC's reporting currency: UK Pound GBX

Institutional shareholders

38.83%Per cent of shares held by top holders
HolderShares% Held
Cevian Capital ABas of 12 Jun 202574.47m8.76%
UBS Asset Management (UK) Ltd.as of 02 Jan 202656.12m6.61%
JPMorgan Chase Bank, NA (Investment Management)as of 02 Jan 202653.15m6.26%
Wellington Management Co. LLPas of 31 Dec 202042.67m5.02%
The Vanguard Group, Inc.as of 02 Jan 202622.90m2.70%
Norges Bank Investment Managementas of 25 Apr 202520.98m2.47%
MFS International (UK) Ltd.as of 02 Jan 202617.30m2.04%
Threadneedle Asset Management Ltd.as of 02 Jan 202614.93m1.76%
FIL Investment Advisors (UK) Ltd.as of 02 Jan 202614.07m1.66%
Jupiter Asset Management Ltd.as of 02 Jan 202613.39m1.58%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.